Workflow
中信建投证券
icon
Search documents
券商晨会精华:全球SOFC进入加速扩产阶段
Xin Lang Cai Jing· 2025-12-12 00:36
智通财经12月12日讯,市场昨日震荡调整,沪深两市成交额1.86万亿,较上一个交易日放量786亿。板 块方面,商业航天、次新股等板块涨幅居前,福建、房地产等板块跌幅居前。截至昨日收盘,沪指跌 0.7%,深成指跌1.27%,创业板指跌1.41%。 天风证券认为,受到电源建设周期及电网输电能力限制,美国电力紧缺给SOFC发展带来新机遇。数据 中心负荷波动极大,对供电可靠性要求极高。SOFC的低冗余配置、功率跟踪优势,使其更适配数据中 心需求。SOFCLCOE已接近燃气发电,天风证券认为随着规模化降本成本优势有望进一步体现。全球 SOFC进入加速扩产阶段。 中金公司:浆纸一体化龙头有望继续获得超额利润 中金公司发布造纸行业2026年展望称,展望2026年,消费需求仍在温和修复阶段,各类纸种供给变化各 异:浆纸系纸种供需仍然宽松,浆价成为行业补库、及去库关键推动力,浆纸一体化龙头有望继续获得 超额利润;箱板瓦楞纸产能已基本收尾,有望率先走出本轮供需失衡周期,迎来产能利用率修复,吨纸 价格中枢同比抬升的业绩修复行情。 中信建投:国内脑机接口公司有望逐步实现商业化应用 中信建投认为,脑机接口产业链上中游的技术进步带来下游 ...
鼓足干劲开新局 砥砺奋进“十五五”
Xin Lang Qi Huo· 2025-12-11 13:52
Group 1 - The central economic work conference has provided direction and fundamental guidelines for high-quality economic development in China, which the company aims to implement as a core task [1] - The company will focus on enhancing political awareness and unifying actions with the central government's scientific judgment on the economic situation, translating conference requirements into actionable business strategies [1][2] Group 2 - The company is committed to serving the real economy by integrating into national strategies and enhancing its role in risk management for enterprises, having served over 1,000 industrial clients in the Chengdu-Chongqing area with a sevenfold increase in client equity scale during the 14th Five-Year Plan [2] - The company plans to continue developing systematic service solutions in areas such as technological innovation, green transformation, and rural revitalization to demonstrate the effectiveness of implementing the conference's spirit [2] Group 3 - The company will focus on talent development to enhance professional capabilities and service levels, aiming to build a resilient financial team capable of facing complex risks [3] - During the 14th Five-Year Plan, the company achieved recognition for three digital research outcomes and plans to strengthen its cross-border service capabilities by collaborating with its parent company [3] Group 4 - The company emphasizes risk control as a priority, aiming to enhance its risk prevention system and comply with regulatory requirements to ensure a safe operational environment [4] - The company is committed to investor protection and reinforcing discipline among employees to maintain compliance and safeguard its operations [4]
年内IPO保荐承销费同比增近4成 头部券商“油水更足”
Xin Lang Cai Jing· 2025-12-11 13:47
Group 1 - The core viewpoint of the article highlights the significant increase in underwriting and sponsorship fees for newly listed companies in 2023, with the highest fees recorded for Moer Technology-U and Muxi Co., Ltd [1] - Muxi Co., Ltd's underwriting and sponsorship fees reached 267 million yuan, making it the second highest for the year, while Moer Technology-U topped the list with fees of 392 million yuan [1] - A total of 102 companies have been listed this year, and with the disclosed results from Muxi Co., Ltd and Angrui Micro, the total underwriting and sponsorship fees for brokers amount to 5.878 billion yuan, reflecting a nearly 40% year-on-year increase [1] Group 2 - Major investment banks such as CITIC Securities, CITIC Jianzhong, Guotai Junan, and Huatai United hold a significant number of projects, indicating their strong market presence [1] - The investment banking sector is facing stricter regulations, leading to penalties for several firms this year [1] - To enhance professional standards, investment banks are increasing compliance and research investments in their team cost structure, which may compress short-term profits but is expected to strengthen long-term competitiveness [1]
交易中心支持江西银行成功发行2025年金融债券
Xin Lang Cai Jing· 2025-12-11 11:17
Core Viewpoint - Jiangxi Bank successfully issued a 3-year financial bond worth 4 billion yuan with a coupon rate of 1.91%, demonstrating strong market interest and confidence in the bank's creditworthiness and growth prospects [1][2] Group 1: Bond Issuance Details - The bond issuance scale is 4 billion yuan with a maturity of 3 years and a coupon rate of 1.91% [1][2] - The overall subscription multiple for the bond was 2.7 times, indicating high demand from investors [1][2] - The lead underwriter and book manager for this bond was CICC, with joint lead underwriters including Industrial Bank, CITIC Securities, and Shenwan Hongyuan Securities [1][2] Group 2: Use of Proceeds - The funds raised will be used to optimize Jiangxi Bank's long-term asset-liability matching structure and to increase stable long-term funding sources [1][2] - The proceeds will also support the development of new long-term asset business [1][2] Group 3: Market Reception and Future Plans - The bond received widespread attention and high recognition from the market, attracting participation from various investment institutions, including banks, funds, and securities firms [1][2] - Jiangxi Bank aims to continue serving urban and rural residents, small and medium-sized enterprises, and the local economy, while enhancing its core business and financial services [1][2] - The trading center plans to strengthen the linkage between primary and secondary markets to improve resource allocation efficiency and fulfill its social responsibility in financial services [1][2]
炒期货绕不开新浪财经?老司机揭秘3个碾压级优势
Xin Lang Cai Jing· 2025-12-11 09:42
伦敦金、纽约 COMEX 黄金、沪金主连、黄金 ETF(如 518880)的行情全整合在一个页面,数据延迟 压在 10 秒内,比银行 APP 快 3 倍。更贴心的是,美元指数、美债收益率这些 "黄金反向指标" 直接贴 在 K 线下方,不用再手动算相关性 —— 上次美债收益率突破 4.5%,系统自动标红提醒 "黄金短期承 压",精准避开回调风险。 二、资讯不瞎喂!直接带买卖点位和机构逻辑 一、不用切 3 个 APP 看行情!内外盘联动一眼摸清 炒黄金最烦的就是 "看伦敦金用 A 软件,盯沪金期货切 B 软件,查黄金 ETF 持仓找 C 软件"—— 上次 美联储降息,伦敦金 5 分钟涨超 20 美元,我切软件的功夫,沪金已经跟涨到位,错过最佳入场点。换 新浪财经才解决这个刚需: 炒黄金最烦的就是 "看伦敦金用 A 软件,盯沪金期货切 B 软件,查黄金 ETF 持仓找 C 软件"—— 上次 美联储降息,伦敦金 5 分钟涨超 20 美元,我切软件的功夫,沪金已经跟涨到位,错过最佳入场点。换 新浪财经才解决这个刚需: 黄金波动全靠 "消息驱动",但多数 APP 只推通稿:"美联储降息 25 基点",却不说对沪金是撑 9 ...
2026银行股前瞻:业绩企稳结构分化,机构看好“再出发”
21世纪经济报道记者林汉垚 见习记者冯紫彤 随着 2026 年日益临近,银行股的业绩走向与结构分化逻辑再次成为机构研报的核心议题。 作为"十五五"规划的开局之年,银行业的经营环境与投资逻辑将如何演变?对于投资者而言,机会藏于何处? 近期,多家券商密集发布年度展望,普遍认为在宏观政策托底、息差有望筑底以及存量风险持续缓释的背景下,2026年上市银行整体业绩大概率将步入温和 修复通道。 然而,几乎所有机构都同时强调,行业内部的结构性分化将成为未来一年的主旋律,马太效应加剧,具备独特客户优势、负债成本管控能力或特定区域禀赋 的银行,将有望领跑新一轮周期。 业绩温和修复成共识,内部分化已成定局 对于2026年的行业整体业绩走势,机构观点呈现出显著共识。多数研报判断,得益于息差收窄压力的缓解和财富管理等中收业务的增长,上市银行营收与净 利润将告别低迷,实现小幅正增长,步入温和的修复通道。 然而,这并非一次普惠式的回暖,"分化"成为各机构策略报告中最高频的关键词之一。 机构普遍指出,银行业增长驱动逻辑正在发生根本性转变,从同质化的规模扩张,转向依赖客户粘性、业务结构和经营效率的差异化竞争。那些在结算业 务、财富管理领域建 ...
星图测控龙虎榜:营业部净卖出355.72万元
具体来看,今日上榜营业部中,第一大买入营业部为国金证券股份有限公司深圳分公司,买入金额为 1555.04万元,第一大卖出营业部为中信建投证券股份有限公司北京东城分公司,卖出金额为2603.52万 元。 近半年该股累计上榜龙虎榜7次,上榜次日股价平均跌0.16%,上榜后5日平均涨4.30%。(数据宝) 星图测控12月11日交易公开信息 | 买/ 卖 | 会员营业部名称 | 买入金额(万元) | 卖出金额(万元) | | --- | --- | --- | --- | | 买一 | 国金证券股份有限公司深圳分公司 | 1555.04 | 495.69 | | 买二 | 东方财富证券股份有限公司拉萨团结路第二证券营业 部 | 1459.29 | 1145.33 | | 买三 | 国信证券股份有限公司深圳红岭中路证券营业部 | 1452.76 | 1416.41 | | 买四 | 东吴证券股份有限公司上海西藏南路证券营业部 | 1442.67 | 1092.20 | | 买五 | 东方财富证券股份有限公司拉萨东环路第二证券营业 部 | 1433.39 | 1034.97 | | 卖一 | 中信建投证券股份有限公司北京 ...
破发连亏股首药控股前三季亏1.55亿 2022年上市募15亿
Zhong Guo Jing Ji Wang· 2025-12-11 07:47
2025年前三季度,公司实现营业收入200万元,同比下滑47.37%;归属于上市公司股东的净利 润-1.55亿元;归属于上市公司股东的扣除非经常性损益的净利润-1.69亿元;经营活动产生的现金流量 净额为-1.72亿元。 | | | 本报告期比 上年同期增 | | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | | 年初至报告期末 | | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | | 不适用 | 2,000,000.00 | -47.37 | | 利润总额 | -50.395.389.71 | 不适用 | -154.767.127.09 | 不适用 | | 归属于上市公司股东的 | -50,395,389.71 | 不适用 | -154.767.127.09 | 不适用 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | -54,587,829.93 | 不适用 | -168.841.741.16 | 不适用 | | 利润 | | | ...
瑞华泰连亏2年3季 A股两募资共7亿IPO国信证券保荐
Zhong Guo Jing Ji Wang· 2025-12-11 07:33
Group 1 - The core viewpoint of the article highlights the financial performance of Ruihua Tai (688323.SH) for the first three quarters of 2025, showing a revenue increase but a net loss [1] - The company achieved an operating revenue of 283 million yuan, representing a year-on-year growth of 18.18% [1] - The net profit attributable to shareholders was a loss of 62.72 million yuan, with a net profit excluding non-recurring gains and losses also showing a loss of 62.96 million yuan [1] - The net cash flow from operating activities reached 108 million yuan, marking a significant increase of 158.34% year-on-year [1] Group 2 - In 2024, the company reported an operating revenue of 339 million yuan, which is a year-on-year increase of 22.88% [3] - The net profit attributable to shareholders for 2024 was a loss of 57.27 million yuan, compared to a loss of 19.60 million yuan in the previous year [3] - The net cash flow from operating activities for 2024 was 138 million yuan, reflecting a growth of 125.20% year-on-year [3] Group 3 - Ruihua Tai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on April 28, 2021, with an initial public offering of 45 million shares at a price of 5.97 yuan per share [4] - The total amount raised from the IPO was 268.65 million yuan, with a net amount of 218.32 million yuan after expenses [4][5] - The company planned to use the raised funds for the Jiaxing high-performance polyimide film project [5]
医药板块迈入“创新兑现期”,港股通创新药ETF嘉实(520970)布局港股创新药产业发展机会
Sou Hu Cai Jing· 2025-12-11 03:31
Core Viewpoint - The innovation drug sector in China is experiencing significant growth due to favorable policy developments, with the introduction of new drug listings in the national medical insurance catalog and commercial insurance, providing a stable policy outlook for innovative drug companies [1][2]. Group 1: Industry Trends - The China Hong Kong Stock Connect Innovation Drug Index increased by 0.30% as of December 11, 2025, with notable gains from companies such as Zhaoyan New Drug (+4.15%) and Rongchang Bio (+2.85%) [1]. - The national medical insurance catalog for 2025 successfully added 114 new drugs, including 50 innovative drugs, achieving a historical high success rate of 88% [1]. - The introduction of dual catalogs for medical insurance and commercial insurance is expected to directly benefit innovative drug companies, indicating a positive industry outlook [1]. Group 2: Market Opportunities - The top ten weighted stocks in the China Hong Kong Stock Connect Innovation Drug Index account for 72.68% of the index, highlighting the concentration of investment in leading innovative drug companies [2]. - The Harvest Innovation Drug ETF (520970) closely tracks the index, providing investors with access to leading companies involved in drug research, development, and production [2]. - Investors without stock accounts can leverage the Hong Kong Stock Connect Innovation Drug ETF linked fund (024700) to capitalize on the growth opportunities in the innovative drug sector [2].